Royce & Associates LP Sells 40,170 Shares of Artivion, Inc. (NYSE:AORT)

Royce & Associates LP trimmed its position in Artivion, Inc. (NYSE:AORT) by 4.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 831,000 shares of the company’s stock after selling 40,170 shares during the period. Royce & Associates LP’s holdings in Artivion were worth $23,758,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of AORT. Lord Abbett & CO. LLC bought a new stake in shares of Artivion in the third quarter valued at about $5,798,000. Tidal Investments LLC lifted its holdings in shares of Artivion by 602.2% in the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock valued at $4,179,000 after purchasing an additional 134,642 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after acquiring an additional 125,668 shares during the last quarter. Sio Capital Management LLC acquired a new stake in shares of Artivion in the third quarter valued at about $3,226,000. Finally, JPMorgan Chase & Co. increased its position in shares of Artivion by 394.9% in the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock valued at $2,606,000 after acquiring an additional 78,120 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors.

Artivion Price Performance

Shares of NYSE AORT opened at $24.15 on Monday. The business’s 50 day moving average price is $28.66 and its two-hundred day moving average price is $27.74. The company has a market cap of $1.02 billion, a PE ratio of -1,207.25 and a beta of 1.79. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a twelve month low of $19.36 and a twelve month high of $32.33.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The business had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. On average, analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on AORT shares. Needham & Company LLC lowered their target price on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Finally, Stifel Nicolaus lowered their target price on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $31.40.

Insider Activity

In other news, SVP Jean F. Holloway sold 5,335 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $145,698.85. Following the transaction, the senior vice president now owns 149,799 shares of the company’s stock, valued at approximately $4,091,010.69. This represents a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James P. Mackin sold 42,156 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $1,151,280.36. Following the completion of the transaction, the chief executive officer now directly owns 663,882 shares in the company, valued at $18,130,617.42. The trade was a 5.97 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,799 shares of company stock valued at $2,356,223. 8.10% of the stock is owned by insiders.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.